Medsolve Dynamics

Medsolve Dynamics

Short, operator-level strategy for radiation oncology and cancer program leaders navigating margin pressure, capital decisions, and AI reality. No fluff. No pitch. Just what the vendor isn't telling you.

  1. قبل يومين

    Ask The Vendor What The Same Software Costs Without The AI. The Unbundled-Price Question

    From 20 years on the vendor side of oncology software sales, the one question that exposes the AI price premium baked into software renewal quotes in 2026. Treatment planning systems, contouring software, registry products, SaaS modules. The AI features were priced higher than the same software would have priced two years ago. Get the unbundled price. medsolvedynamics.com | team@medsolvedynamics.com

    ١ د

  2. قبل ٤ أيام

    When I Was On The Vendor Side: The AI Demo That Skipped The Workflow Question

    A vendor-side story Yoel Bakas has watched play out dozens of times in radiation oncology. A software demo runs without anyone asking what is actually broken in the customer's workflow. The tool gets relabeled AI-enabled a year later. Until the customer understands what is broken, it does not matter what the tool is. AI in radiation oncology, workflow design, vendor evaluation, capital decision. medsolvedynamics.com | team@medsolvedynamics.com

    ١ د

  3. قبل ٥ أيام

    Why Your LINAC's Unbooked Hours Are The Cheapest Margin Audit You Will Run In 2026

    From 20 years on the vendor side of LINAC capital and service negotiations, the data point most radiation oncology programs do not see with the same precision the vendor sees it: their own unbooked machine hours. Every unbooked hour is a fixed cost paid for and not recovered. The 15-minute utilization audit is the cheapest margin discipline in the 2026 reimbursement environment. medsolvedynamics.com | team@medsolvedynamics.com

    ١ د

  4. ١٥ مايو

    What Does This Commit Us To In Year Five? The Question Every Oncology Capital Decision Needs

    Capital decisions hold up when the year-five reality is considered before the signature. They break when only year-one numbers are. From 20 years on the vendor side and now on the program side, the year-five question that protects margin through a multi-year operating commitment in radiation oncology. medsolvedynamics.com | team@medsolvedynamics.com

    ١ د

  5. ١٣ مايو

    The Proforma Altitude Problem In 2026 Oncology Capital Decisions

    From 20 years on the vendor side and now on the program side, the math that wins capital approval is not the math the program runs in year two. The reimbursement environment moved more than the headline rate change. medsolvedynamics.com | team@medsolvedynamics.com

    ١ د

  6. ١٢ مايو

    Adding Benign Disease Is A Referral Decision, Not An Equipment Decision

    Benign disease radiation uses LINAC capacity that is already paid for in most programs. The growth question is referral pathway, not capital. From 20 years of watching programs add and grow service lines. medsolvedynamics.com | team@medsolvedynamics.com

    ١ د

  7. ١١ مايو

    Theranostics Capital Decisions Are Build-Or-Partner Decisions, Not Product Decisions

    From 20 years on the vendor side and now on the program side, the capital form decision that gets skipped on most theranostics service-line additions. Build or partner sets the next decade. With reference to Kenneth Brooks and Christine Stone’s published build case study at Wellstar Health System. medsolvedynamics.com | team@medsolvedynamics.com

    **ASE.Web.Podcasts.Duration.Minute.two**

  8. ٨ مايو

    Capital Is A 7-10 Year Commitment: The Math Most Proformas Skip

    Capital decisions in radiation oncology are not point-in-time decisions. The proforma that wins approval at signature is not the proforma that runs the program in year five. From 20 years on the vendor side and now on the program side, the math that protects margin through a full capital cycle. medsolvedynamics.com | team@medsolvedynamics.com

    ١ د
مشاهدة الكل (٥٦)

التقييمات والمراجعات

٥
من ٥
‫٢ من التقييمات‬

حول

Short, operator-level strategy for radiation oncology and cancer program leaders navigating margin pressure, capital decisions, and AI reality. No fluff. No pitch. Just what the vendor isn't telling you.

المعلومات

  • صناع العمل
    Medsolve Dynamics
  • سنوات النشاط
    ٢٠٢٦
  • الحلقات
    ٥٦
  • التقييم
    ملائم
  • حقوق النشر
    © 2026 Medsolve Dynamics